Combining a beta2-agonist with a face mask to prevent exercise-induced bronchoconstriction

Allergy. 2000 Jul;55(7):672-5. doi: 10.1034/j.1398-9995.2000.00558.x.


Background: In this study, we aimed to test the effect of combining a P2-agonist with a heat- and moisture-exchanging cellulose face mask in patients with bronchoconstriction induced by exercise in cold air.

Methods: Nine allergic, asthmatic patients with a history of adverse reaction to exercise were tested on an ergometric bicycle at a temperature of approximately -10 degrees C. They were in turn given no treatment, given premedication with a beta2-agonist, allowed to breathe through a heat- and moisture-exchanging cellulose face mask, and given both premedication and the face mask. After each treatment regimen, they were subjected to provocation with exercise and cold air.

Results: The decrease in FEV, was greatest with no therapy (mean maximal change: 27%), and this diminished when the face mask was used (mean maximal change: 12%,) or premedication with a 32-agonist was given (mean maximal change: 7%); no decrease in FEV1 occurred with the combination of agonist and face mask.

Conclusions: The results suggest that different mechanisms are involved in the pathophysiology of exercise-induced bronchoconstriction (EIB). This finding may be of importance for asthmatic athletes who train and compete in a cold climate and are affected by small changes in their lung function.

Publication types

  • Clinical Trial

MeSH terms

  • Adrenergic beta-2 Receptor Agonists*
  • Adult
  • Asthma, Exercise-Induced / drug therapy*
  • Asthma, Exercise-Induced / prevention & control*
  • Cellulose
  • Cold Temperature
  • Combined Modality Therapy
  • Ethanolamines / therapeutic use
  • Female
  • Forced Expiratory Volume
  • Formoterol Fumarate
  • Hot Temperature
  • Humans
  • Humidity
  • Male
  • Masks*


  • Adrenergic beta-2 Receptor Agonists
  • Ethanolamines
  • Cellulose
  • Formoterol Fumarate